Radiopharm Theranostics Limited
RADX
$7.03
-$0.42-5.64%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,088.17% | 1,646.65% | -- | 587.41% | 0.46% |
| Total Other Revenue | 427.76% | -6.25% | -122.34% | -97.62% | -73.06% |
| Total Revenue | 530.34% | 55.97% | -94.37% | -81.37% | -69.61% |
| Cost of Revenue | 42.29% | 9.42% | -17.38% | -5.98% | 7.54% |
| Gross Profit | 5.79% | -0.12% | -5.49% | -21.37% | -43.40% |
| SG&A Expenses | 3.78% | -4.01% | -11.43% | -5.31% | -0.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.08% | 4.01% | -15.08% | -5.71% | 4.22% |
| Operating Income | 1.54% | 1.73% | 2.12% | -8.39% | -20.22% |
| Income Before Tax | 21.07% | 15.19% | 9.41% | -9.99% | -34.66% |
| Income Tax Expenses | 7.58% | 117.89% | 495.65% | 300.46% | 148.24% |
| Earnings from Continuing Operations | 21.01% | 15.01% | 9.11% | -10.23% | -34.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 549.09% | -111.18% | -115.33% | -115.13% | -- |
| Net Income | 21.10% | 13.91% | 6.63% | -11.89% | -34.81% |
| EBIT | 1.54% | 1.73% | 2.12% | -8.39% | -20.22% |
| EBITDA | -0.03% | 0.80% | 1.81% | -9.97% | -23.85% |
| EPS Basic | 85.56% | 68.66% | 53.38% | 24.22% | -10.95% |
| Normalized Basic EPS | 82.38% | 65.09% | 49.40% | 26.17% | 2.28% |
| EPS Diluted | 85.56% | 68.66% | 53.38% | 24.22% | -10.95% |
| Normalized Diluted EPS | 82.38% | 65.09% | 49.40% | 26.17% | 2.28% |
| Average Basic Shares Outstanding | 438.49% | 348.56% | 243.78% | 139.48% | 26.36% |
| Average Diluted Shares Outstanding | 438.49% | 348.56% | 243.78% | 139.48% | 26.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |